Advertisement

Heart Failure in Rheumatic Disease

Secular Trends and Novel Insights

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • van Riet E.E.S.
        • Hoes A.W.
        • Wagenaar K.P.
        • et al.
        Comment on “Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review.
        Eur J Heart Fail. 2016; 18: 242-252
        • Heidenreich P.A.
        • Bozkurt B.
        • Aguilar D.
        • et al.
        2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
        J Am Coll Cardiol. 2022; 79https://doi.org/10.1016/j.jacc.2021.12.012
        • McDonagh T.A.
        • Metra M.
        • Adamo M.
        • et al.
        2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
        Eur Heart J. 2021; 42: 3599-3726
        • Mantel Ä.
        • Holmqvist M.
        • Andersson D.C.
        • et al.
        Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure.
        J Am Coll Cardiol. 2017; 69: 1275-1285
        • Løgstrup B.B.
        • Ellingsen T.
        • Pedersen A.B.
        • et al.
        Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study.
        Eur J Clin Invest. 2018; 48: 1-8
        • Crowson C.S.
        • Nicola P.J.
        • Kremers H.M.
        • et al.
        How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?.
        Arthritis Rheum. 2005; 52: 3039-3044
        • Nicola P.J.
        • Maradit-Kremers H.
        • Roger V.L.
        • et al.
        The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years.
        Arthritis Rheum. 2005; 52: 412-420
        • Løgstrup B.B.
        • Ellingsen T.
        • Pedersen A.B.
        • et al.
        Heart Failure and Ischemic Heart Disease in Patients With Rheumatoid Arthritis.
        J Am Coll Cardiol. 2017; 70: 3069-3071
        • Ferreira M.B.
        • Fonseca T.
        • Costa R.
        • et al.
        Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study.
        Eur J Intern Med. 2021; 85: 41-49
        • Solomon D.H.
        • Karlson E.W.
        • Rimm E.B.
        • et al.
        Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.
        Circulation. 2003; 107: 1303-1307
        • Peters M.J.L.
        • Van Halm V.P.
        • Voskuyl A.E.
        • et al.
        Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study.
        Arthritis Care Res. 2009; 61: 1571-1579
        • Khalid Y.
        • Dasu N.
        • Shah A.
        • et al.
        Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis.
        ESC Hear Fail. 2020; 7: 3745-3753
        • Baniaamam M.
        • Paulus W.J.
        • Blanken A.B.
        • et al.
        The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review.
        Expert Opin Biol Ther. 2018; 18: 585-594
        • Solomon D.H.
        • Greenberg J.
        • Curtis J.R.
        • et al.
        Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A consortium of rheumatology researchers of North America registry study.
        Arthritis Rheumatol. 2015; 67: 1995-2003
        • Nissen S.E.
        • Yeomans N.D.
        • Solomon D.H.
        • et al.
        Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
        N Engl J Med. 2016; 375: 2519-2529
        • Moder K.G.
        • Miller T.D.
        • Tazelaar H.D.
        Cardiac involvement in systemic lupus erythematosus.
        Mayo Clin Proc. 1999; 74: 275-284
        • Kim C.H.
        • Al-Kindi S.G.
        • Jandali B.
        • et al.
        Incidence and risk of heart failure in systemic lupus erythematosus.
        Heart. 2017; 103: 227-233
        • Chen S.K.
        • Barbhaiya M.
        • Fischer M.A.
        • et al.
        Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients.
        Semin Arthritis Rheum. 2019; 49: 389-395
        • Dhakal B.P.
        • Kim C.H.
        • Al-Kindi S.G.
        • et al.
        Heart failure in systemic lupus erythematosus.
        Trends Cardiovasc Med. 2018; 28: 187-197
        • Yafasova A.
        • Fosbøl E.L.
        • Schou M.
        • et al.
        Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus.
        J Am Coll Cardiol. 2021; 77: 1717-1727
        • Manzi S.
        • Meilahn E.N.
        • Rairie J.E.
        • et al.
        Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study.
        Am J Epidemiol. 1997; 145: 408-415
        • Jonsson H.
        • Nived O.
        • Sturfelt G.
        Outcome in Systemic Lupus Erythematosus - A prospective Study of Patients from a Defined Population.
        Medicne. 1989; 68: 141-150
        • Bae K.H.
        • Hong J.B.
        • Choi Y.J.
        • et al.
        Association of Congestive Heart Failure and Death with Ankylosing Spondylitis : A Nationwide Longitudinal Cohort Study in Korea.
        J Korean Neurosurg Soc. 2019; 62: 217-224
        • Han C.
        • Robinson D.W.J.
        • Hackett M.V.
        • et al.
        Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
        J Rheumatol. 2006; 33: 2167-2172
        • Castaneda S.
        • Gonzalez-Juanatey C.
        • Gonzalez-Gay M.A.
        Inflammatory Arthritis and Heart Disease.
        Curr Pharm Des. 2018; 24: 262-280
        • Heslinga S.C.
        • Van Dongen C.J.
        • Konings T.C.
        • et al.
        Diastolic left ventricular dysfunction in ankylosing spondylitis--a systematic review and meta-analysis.
        Semin Arthritis Rheum. 2014; 44: 14-19
        • Ahlehoff O.
        • Gislason G.H.
        • Charlot M.
        • et al.
        Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study.
        J Intern Med. 2011; 270: 147-157
        • Koppikar S.
        • Colaco K.
        • Harvey P.
        • et al.
        Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study.
        Arthritis Care Res (Hoboken). 2021; 74: 1244-1253
        • Khalid U.
        • Ahlehoff O.
        • Gislason G.H.
        • et al.
        Psoriasis and risk of heart failure: a nationwide cohort study.
        Eur J Heart Fail. 2014; 16: 743-748
        • Kondratiouk S.
        • Udaltsova N.
        • Klatsky A.L.
        Associations of psoriatic arthritis and cardiovascular conditions in a large population.
        Perm J. 2008; 12: 4-8
        • Gladman D.D.
        • Ang M.
        • Su L.
        • et al.
        Cardiovascular morbidity in psoriatic arthritis.
        Ann Rheum Dis. 2009; 68: 1131-1135
        • Kibari A.
        • Cohen A.D.
        • Gazitt T.
        • et al.
        Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study.
        Clin Rheumatol. 2019; 38: 2069-2075
        • Polachek A.
        • Touma Z.
        • Anderson M.
        • et al.
        Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies.
        Arthritis Care Res. 2017; 69: 67-74
        • Lottmann K.
        • Chen X.
        • Schädlich P.K.
        Association between gout and all-cause as well as cardiovascular mortality: A systematic review.
        Curr Rheumatol Rep. 2012; 14: 195-203
        • Colantonio L.D.
        • Saag K.G.
        • Singh J.A.
        • et al.
        Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study.
        Arthritis Res Ther. 2020; 22: 86
        • Huang H.
        • Huang B.
        • Li Y.
        • et al.
        Uric acid and risk of heart failure: A systematic review and meta-analysis.
        Eur J Heart Fail. 2014; 16: 15-24
        • Krishnan E.
        Gout and the risk for incident heart failure and systolic dysfunction.
        BMJ Open. 2012; 2: 1-8
        • Wu X.
        • Jian G.
        • Tang Y.
        • et al.
        Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities.
        Nutr Metab Cardiovasc Dis. 2020; 30: 666-673
        • Bartels C.M.
        • Kind A.J.H.
        • Everett C.
        • et al.
        Low frequency of primary lipid screening among Medicare patients with rheumatoid arthritis.
        Arthritis Rheum. 2011; 63: 1221-1230
        • Toms T.E.
        • Panoulas V.F.
        • Douglas K.M.J.
        • et al.
        Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk?.
        Ann Rheum Dis. 2010; 69: 683-688
        • Alemao E.
        • Cawston H.
        • Bourhis F.
        • et al.
        Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis.
        Rheumatol (United Kingdom). 2017; 56: 777-786
        • Esdaile J.M.
        • Abrahamowicz M.
        • Grodzicky T.
        • et al.
        Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.
        Arthritis Rheum. 2001; 44: 2331-2337
        • Van Breukelen-van der Stoep D.F.
        • Van Zeben D.
        • Klop B.
        • et al.
        Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis.
        Rheumatol (United Kingdom). 2016; 55: 1210-1216
        • Svensson A.L.
        • Christensen R.
        • Persson F.
        • et al.
        Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: Protocol for a multicentre randomised controlled trial.
        BMJ Open. 2016; 6https://doi.org/10.1136/bmjopen-2015-009134
        • Paulus W.J.
        • Tschöpe C.
        A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
        J Am Coll Cardiol. 2013; 62: 263-271
        • Westermann D.
        • Lindner D.
        • Kasner M.
        • et al.
        Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.
        Circ Hear Fail. 2011; 4: 44-52
        • Van Linthout S.
        • Tschöpe C.
        Inflammation – Cause or Consequence of Heart Failure or Both?.
        Curr Heart Fail Rep. 2017; 14: 251-265
        • Porrello Enzo
        • Mahmoud Ahmed
        • Simpson Emma
        • et al.
        Transient Regenerative Potential of the Neonatal Mouse Heart.
        Science. 2011; 331 (.Transient): 1078-1080
        • Farache Trajano L.
        • Smart N.
        Immunomodulation for optimal cardiac regeneration: insights from comparative analyses.
        Npj Regen Med. 2021; 6: 1-11
        • Bansal Shyam S.
        • Ismahil Mohamad
        • Goel Mehek
        • et al.
        Activated T-Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure.
        Circ Hear Fail. 2017; 10 (Activated): e003688
        • Dolejsi T.
        • Delgobo M.
        • Schuetz T.
        • et al.
        Adult T-cells impair neonatal cardiac regeneration.
        Eur Heart J. 2022; https://doi.org/10.1093/eurheartj/ehac153
        • Garbern J.C.
        • Lee R.T.
        Heart regeneration: 20 years of progress and renewed optimism.
        Dev Cell. 2022; 57: 424-439
        • Torre-Amione G.
        • Kapadia S.
        • Benedict C.
        • et al.
        Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD).
        J Am Coll Cardiol. 1996; 27: 1201-1206
        • Deswal A.
        • Petersen N.J.
        • Feldman A.M.
        • et al.
        Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST).
        Circulation. 2001; 103: 2055-2059
        • Libby P.
        • Ridker P.M.
        • Hansson G.K.
        Inflammation in Atherosclerosis. From Pathophysiology to Practice.
        J Am Coll Cardiol. 2009; 54: 2129-2138
        • Libby P.
        Role of Inflammation in Atherosclerosis Associated with Rheumatoid Arthritis.
        Am J Med. 2008; 121https://doi.org/10.1016/j.amjmed.2008.06.014
        • Elenkov I.J.
        • Wilder R.L.
        • Chrousos G.P.
        • et al.
        The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
        Pharmacol Rev. 2000; 52: 595-638
        • Ahlehoff O.
        • Gislason G.H.
        • Jorgensen C.H.
        • et al.
        Psoriasis and risk of atrial fibrillation and ischaemic stroke: A Danish Nationwide Cohort Study.
        Eur Heart J. 2012; 33: 2054-2064
        • Lazzerini P.E.
        • Capecchi P.L.
        • Laghi-Pasini F.
        Assessing QT interval in patients with autoimmune chronic inflammatory diseases: Perils and pitfalls.
        Lupus Sci Med. 2016; 3: 1-5
        • Santos R.C.
        • Figueiredo V.N.
        • Martins L.C.
        • et al.
        Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure.
        Rev Assoc Med Bras. 2012; 58: 698-702
        • Mann D.L.
        • McMurray J.J.V.
        • Packer M.
        • et al.
        Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
        Circulation. 2004; 109: 1594-1602
        • Chung C.P.
        • Giles J.T.
        • Petri M.
        • et al.
        Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: Comparison with control subjects from the multi-ethnic study of atherosclerosis.
        Semin Arthritis Rheum. 2012; 41: 535-544
        • Lv S.
        • Han M.
        • Yi R.
        • et al.
        Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis.
        Int J Clin Pract. 2014; 68: 520-528
        • Fakharian A.
        • Barati S.
        • Mirenayat M.
        • et al.
        Evaluation of adalimumab effects in managing severe cases of COVID-19 : A randomized controlled trial.
        Int Immunopharmacol. 2021; 99: 107961
        • Everett B.M.
        • Siddiqi H.K.
        Heart Failure, the Inflammasome, and Interleukin-1β: Prognostic and Therapeutic?.
        J Am Coll Cardiol. 2019; 73: 1026-1028
        • Ridker P.M.
        • Everett B.M.
        • Thuren T.
        • et al.
        Antiinflammatory therapy with canakinumab for atherosclerotic disease.
        N Engl J Med. 2017; 377: 1119-1131
        • Buckley Leo
        • Carbone Salvatore
        • Trankle Cory
        • et al.
        Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post-Hoc Pooled Analysis of Two Clinical Trials.
        J Cardiovasc Pharmacol. 2018; 72 (Effect): 68-70
        • Kobayashi H.
        • Kobayashi Y.
        • Giles J.T.
        • et al.
        Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: Assessed using 3.0 tesla cardiac magnetic resonance imaging.
        J Rheumatol. 2014; 41: 1916-1921
        • Yokoe I.
        • Kobayashi H.
        • Kobayashi Y.
        • et al.
        Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms.
        Scand J Rheumatol. 2018; 47: 364-370
        • Yano T.
        • Osanami A.
        • Shimizu M.
        • et al.
        Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting.
        ESC Hear Fail. 2019; 6: 894-897
        • Meyer M.A.S.
        • Wiberg S.
        • Grand J.
        • et al.
        Treatment Effects of Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest (The IMICA Trial): A Double-Blinded, Placebo-Controlled, Single-Center, Randomized, Clinical Trial.
        Circulation. 2021; 143: 1841-1851
        • Torre-Amione G.
        • Anker S.D.
        • Bourge R.C.
        • et al.
        Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.
        Lancet (London, England). 2008; 371: 228-236
        • Torre-Amione G.
        • Sestier F.
        • Radovancevic B.
        • et al.
        Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial.
        J Am Coll Cardiol. 2004; 44: 1181-1186
        • Fishel R.S.
        • Eisenberg S.
        • Shai S.Y.
        • et al.
        Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle.
        Hypertens (Dallas, Tex 1979). 1995; 25: 343-349
        • Garg R.
        • Yusuf S.
        Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
        JAMA. 1995; 273: 1450-1456
        • McMurray J.J.V.
        • Packer M.
        • Desai A.S.
        • et al.
        Angiotensin-neprilysin inhibition versus enalapril in heart failure.
        N Engl J Med. 2014; 371: 993-1004
        • Ò Miró
        • Takagi K.
        • Gayat E.
        • et al.
        CORT-AHF Study: Effect on Outcomes of Systemic Corticosteroid Therapy During Early Management Acute Heart Failure.
        JACC Heart Fail. 2019; 7: 834-845
        • Ain Q.U.
        • Batool M.
        • Choi S.
        TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches.
        Molecules. 2020; 25https://doi.org/10.3390/molecules25030627
        • Champion S.
        • Lapidus N.
        • Cherié G.
        • et al.
        Pentoxifylline in heart failure: A meta-analysis of clinical trials.
        Cardiovasc Ther. 2014; 32: 159-162
        • Aukrust P.
        • Yndestad A.
        • Damås J.K.
        • et al.
        Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin.
        Autoimmun Rev. 2004; 3: 221-227
        • Moreira D.M.
        • Vieira J.L.
        • Mascia Gottschall C.A.
        The Effects of METhotrexate Therapy on the Physical Capacity of Patients With ISchemic Heart Failure: A Randomized Double-Blind, Placebo-Controlled Trial (METIS Trial).
        J Card Fail. 2009; 15: 828-834
        • Van Tassell B.W.
        • Canada J.
        • Carbone S.
        • et al.
        Interleukin-1 blockade in recently decompensated systolic heart failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
        Circ Hear Fail. 2017; 10: 1-11
        • Van Tassell B.W.
        • Arena R.
        • Biondi-Zoccai G.
        • et al.
        Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).
        Am J Cardiol. 2014; 113: 321-327
        • Trankle C.R.
        • Canada J.M.
        • Cei L.
        • et al.
        Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein.
        Am J Cardiol. 2018; 122: 1366-1370
        • Chung E.S.
        • Packer M.
        • Lo K.H.
        • et al.
        Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH.
        Circulation. 2003; 107: 3133-3140
        • Givertz M.M.
        • Anstrom K.J.
        • Redfield M.M.
        • et al.
        Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
        Circulation. 2015; 131: 1763-1771
        • Hare J.M.
        • Mangal B.
        • Brown J.
        • et al.
        Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
        J Am Coll Cardiol. 2008; 51: 2301-2309
        • Tang L.
        • Wang H.
        • Ziolo M.T.
        Targeting NOS as a therapeutic approach for heart failure.
        Pharmacol Ther. 2014; 142: 306-315
        • Tavazzi L.
        • Maggioni A.P.
        • Marchioli R.
        • et al.
        Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
        Lancet (London, England). 2008; 372: 1231-1239
        • Kjekshus J.
        • Apetrei E.
        • Barrios V.
        • et al.
        Rosuvastatin in older patients with systolic heart failure.
        N Engl J Med. 2007; 357: 2248-2261
        • Deftereos S.
        • Giannopoulos G.
        • Panagopoulou V.
        • et al.
        Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study.
        JACC Heart Fail. 2014; 2: 131-137
        • Wohlford G.F.
        • Van Tassell B.W.
        • Billingsley H.E.
        • et al.
        Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure.
        J Cardiovasc Pharmacol. 2020; 77: 49-60